(LEGN) Legend Biotech - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 3.107m USD | Total Return: -46.7% in 12m

Stock Cell Therapies, Oncology, Cancer Treatment
Total Rating 17
Risk 41
Buy Signal -0.62
Biotechnology +0.2
Biotechnology +1.0
Market Cap: 3,107m
Avg Trading Vol: 25.8M USD
ATR: 4.87%
Peers RS (IBD): 3.3
Risk 5d forecast
Volatility49.1%
Rel. Tail Risk-8.07%
Reward TTM
Sharpe Ratio-1.16
Alpha-57.26
Character TTM
Beta0.326
Beta Downside0.163
Drawdowns 3y
Max DD78.24%
CAGR/Max DD-0.35
EPS (Earnings per Share) EPS (Earnings per Share) of LEGN over the last years for every Quarter: "2021-03": -0.3, "2021-06": -0.32, "2021-09": -0.43, "2021-12": -0.3, "2022-03": -0.26, "2022-06": -0.33, "2022-09": -0.37, "2022-12": -0.62, "2023-03": -0.68, "2023-06": -1.14, "2023-09": -0.34, "2023-12": -0.8, "2024-03": -0.16, "2024-06": -0.1, "2024-09": -0.6838, "2024-12": 0.14, "2025-03": -0.54, "2025-06": -0.34, "2025-09": -0.11, "2025-12": -0.16, "2026-03": 0,
EPS CAGR: 9.20%
EPS Trend: 50.1%
Last SUE: -0.05
Qual. Beats: 0
Revenue Revenue of LEGN over the last years for every Quarter: 2021-03: 14.304, 2021-06: 20.834, 2021-09: 17.037, 2021-12: 38.995, 2022-03: 41.332, 2022-06: 11.971, 2022-09: 27.361, 2022-12: 27.633, 2023-03: 36.336, 2023-06: 73.33, 2023-09: 96.013, 2023-12: 79.464, 2024-03: 93.991, 2024-06: 186.523, 2024-09: 160.205, 2024-12: 186.522, 2025-03: 195.053, 2025-06: 255.058, 2025-09: 272.33, 2025-12: 307.636722, 2026-03: null,
Rev. CAGR: 70.79%
Rev. Trend: 90.4%
Last SUE: -0.09
Qual. Beats: 0
Risks
Technicals: choppy
Description: LEGN Legend Biotech March 04, 2026

Legend Biotech Corp. is a biopharmaceutical company focused on cell therapies for oncology. The company develops and commercializes treatments in the United States, China, and Europe.

Their primary product, cilta-cel, is a CAR-T therapy for multiple myeloma. CAR-T therapy is a complex and personalized treatment that involves modifying a patients own immune cells. Legend Biotech also has a pipeline of earlier-stage autologous CAR-T candidates for various cancers and is developing allogeneic CAR-T and CAR-NK therapies.

The company operates under a business model that includes strategic collaborations, such as its agreement with Janssen Biotech for cilta-cel and a license agreement with Novartis Pharma AG. These partnerships are common in the biotechnology sector, enabling shared development costs and broader market access.

For more detailed financial and operational insights, ValueRay offers comprehensive company profiles.

Headlines to Watch Out For
  • CAR-T therapy sales drive revenue growth
  • Clinical trial results impact future product value
  • Regulatory approvals critical for market access
  • Collaboration milestones provide significant income
Piotroski VR‑10 (Strict, 0-10) 2.5
Net Income: -297.0m TTM > 0 and > 6% of Revenue
FCF/TA: -0.13 > 0.02 and ΔFCF/TA -3.84 > 1.0
NWC/Revenue: 59.29% < 20% (prev 160.4%; Δ -101.1% < -1%)
CFO/TA -0.11 > 3% & CFO -193.6m > Net Income -297.0m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 1.96 > 1.5 & < 3
Outstanding Shares: last quarter (184.7m) vs 12m ago 102.1% < -2%
Gross Margin: 60.33% > 18% (prev 0.63%; Δ 5.97k% > 0.5%)
Asset Turnover: 60.52% > 50% (prev 37.56%; Δ 22.97% > 0%)
Interest Coverage Ratio: -12.69 > 6 (EBITDA TTM -243.5m / Interest Expense TTM 21.5m)
Altman Z'' -4.98
A: 0.35 (Total Current Assets 1.25b - Total Current Liabilities 636.4m) / Total Assets 1.73b
B: -1.13 (Retained Earnings -1.96b / Total Assets 1.73b)
C: -0.16 (EBIT TTM -272.5m / Avg Total Assets 1.70b)
D: -2.42 (Book Value of Equity -1.75b / Total Liabilities 723.6m)
Altman-Z'' Score: -4.98 = D
Beneish M -2.74
DSRI: 1.22 (Receivables 250.3m/124.9m, Revenue 1.03b/627.2m)
GMI: 1.04 (GM 60.33% / 62.60%)
AQI: 0.44 (AQ_t 0.05 / AQ_t-1 0.11)
SGI: 1.64 (Revenue 1.03b / 627.2m)
TATA: -0.06 (NI -297.0m - CFO -193.6m) / TA 1.73b)
Beneish M-Score: -2.74 (Cap -4..+1) = A
What is the price of LEGN shares? As of April 01, 2026, the stock is trading at USD 18.09 with a total of 1,200,430 shares traded.
Over the past week, the price has changed by +5.85%, over one month by -1.90%, over three months by -16.79% and over the past year by -46.68%.
Is LEGN a buy, sell or hold? Legend Biotech has received a consensus analysts rating of 4.45. Therefore, it is recommended to buy LEGN.
  • StrongBuy: 11
  • Buy: 10
  • Hold: 1
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the LEGN price?
ISSUER TARGET UP/DOWN
Wallstreet Target Price 58.1 221.1%
Analysts Target Price 58.1 221.1%
LEGN Fundamental Data Overview March 29, 2026
P/E Forward = 80.0
P/S = 3.02
P/B = 3.1007
Revenue TTM = 1.03b USD
EBIT TTM = -272.5m USD
EBITDA TTM = -243.5m USD
Long Term Debt = 171.9m USD (from longTermDebt, two quarters ago)
Short Term Debt = 326.5m USD (from shortTermDebt, last quarter)
Debt = 413.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -488.2m USD (from netDebt column, last quarter)
Enterprise Value = 2.57b USD (3.11b + Debt 413.7m - CCE 948.6m)
Interest Coverage Ratio = -12.69 (Ebit TTM -272.5m / Interest Expense TTM 21.5m)
EV/FCF = -11.15x (Enterprise Value 2.57b / FCF TTM -230.8m)
FCF Yield = -8.97% (FCF TTM -230.8m / Enterprise Value 2.57b)
FCF Margin = -22.40% (FCF TTM -230.8m / Revenue TTM 1.03b)
Net Margin = -28.83% (Net Income TTM -297.0m / Revenue TTM 1.03b)
Gross Margin = 60.33% ((Revenue TTM 1.03b - Cost of Revenue TTM 408.7m) / Revenue TTM)
Gross Margin QoQ = 59.68% (prev 57.66%)
Tobins Q-Ratio = 1.48 (Enterprise Value 2.57b / Total Assets 1.73b)
Interest Expense / Debt = 1.34% (Interest Expense 5.52m / Debt 413.7m)
Taxrate = 21.0% (US default 21%)
NOPAT = -215.3m (EBIT -272.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.96 (Total Current Assets 1.25b / Total Current Liabilities 636.4m)
Debt / Equity = 0.41 (Debt 413.7m / totalStockholderEquity, last quarter 1.00b)
 Debt / EBITDA = 2.00 (negative EBITDA) (Net Debt -488.2m / EBITDA -243.5m)
 Debt / FCF = 2.12 (negative FCF - burning cash) (Net Debt -488.2m / FCF TTM -230.8m)
 Total Stockholder Equity = 1.02b (last 4 quarters mean from totalStockholderEquity)
RoA = -17.45% (Net Income -297.0m / Total Assets 1.73b)
RoE = -29.22% (Net Income TTM -297.0m / Total Stockholder Equity 1.02b)
RoCE = -22.93% (EBIT -272.5m / Capital Employed (Equity 1.02b + L.T.Debt 171.9m))
 RoIC = -16.20% (negative operating profit) (NOPAT -215.3m / Invested Capital 1.33b)
 WACC = 6.42% (E(3.11b)/V(3.52b) * Re(7.13%) + D(413.7m)/V(3.52b) * Rd(1.34%) * (1-Tc(0.21)))
Discount Rate = 7.13% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: 100.0 | Cagr: 2.25%
 [DCF] Fair Price = unknown (Cash Flow -230.8m)
 EPS Correlation: 50.07 | EPS CAGR: 9.20% | SUE: -0.05 | # QB: 0
Revenue Correlation: 90.37 | Revenue CAGR: 70.79% | SUE: -0.09 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.05 | Chg7d=-0.103 | Chg30d=-0.095 | Revisions Net=-1 | Analysts=1
EPS current Year (2026-12-31): EPS=0.10 | Chg7d=-0.290 | Chg30d=-0.232 | Revisions Net=-2 | Growth EPS=+106.4% | Growth Revenue=+39.6%
EPS next Year (2027-12-31): EPS=1.12 | Chg7d=-0.030 | Chg30d=-0.632 | Revisions Net=-1 | Growth EPS=+998.0% | Growth Revenue=+27.3%
[Analyst] Revisions Ratio: -1.00 (0 Up / 1 Down within 30d for Next Quarter)
Additional Sources for LEGN Stock Fund Manager Positions: Dataroma · Stockcircle